Skip to main content
Premium Trial:

Request an Annual Quote

Remember, Pfizer, There's No Such Thing as Bad News

Pfizer can't be pleased to be making such frequent appearances in the media. New York Times reports that expert reviewers have concluded that Pfizer "manipulated the publication of scientific studies to bolster the use of its epilepsy drug Neurontin for other disorders, while suppressing research that did not support those uses," according to the article. It continues:

Pfizer's tactics included delaying the publication of studies that had found no evidence the drug worked for some other disorders, "spinning" negative data to place it in a more positive light, and bundling negative findings with positive studies to neutralize the results, according to written reports by the experts, who analyzed the documents at the request of the plaintiffs' lawyers.

Pfizer released a statement denying any manipulation of the data, but it must've been tough to get that out with its reorg going on. This Wall Street Journal article has details on the pharma's plans to restructure, including efforts to "create divisions that are more global in focus, and will move certain drug-development functions out of the traditional research arm and into the commercial groups that also handle sales and marketing." Changes will take place in January.

 

The Scan

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.